Liaoning He Eye Hospital Group Valuation

Q: What is the Fair Price of 301103 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301103 (CN¥22.34) is trading above our estimate of [[fair value]] (CN¥0.25)

Is 301103 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301103 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301103 (CN¥22.34) is trading above our estimate of fair value (CN¥0.25)

Significantly Below Fair Value: 301103 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301103?

Key metric: As 301103 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 301103. This is calculated by dividing 301103's market cap by their current revenue.
What is 301103's PS Ratio?
PS Ratio	3.1x
Sales	CN¥1.11b
Market Cap	CN¥3.47b

301103 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	64.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 301103's PS Ratio compare to its peers?

The above table shows the PS ratio for 301103 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.2x
300962 Zhongjin Irradiation	12x	n/a	CN¥4.3b
300244 Dian Diagnostics GroupLtd	0.6x	8.2%	CN¥7.8b
600682 Nanjing Xinjiekou Department Store	1.4x	9.4%	CN¥9.6b
002622 Whole Shine Medical Technology	2.8x	n/a	CN¥2.4b
301103 Liaoning He Eye Hospital Group	3.1x	n/a	CN¥3.5b

Price-To-Sales vs Peers: 301103 is good value based on its Price-To-Sales Ratio (3.1x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does 301103's PS Ratio compare vs other companies in the CN Healthcare Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap
601607 Shanghai Pharmaceuticals Holding	0.3x	9.5%	US$9.88b
600998 Jointown Pharmaceutical Group	0.2x	8.0%	US$3.53b
000028 China National Accord Medicines	0.2x	5.7%	US$2.10b
000950 C.Q. Pharmaceutical Holding	0.1x	10.1%	US$1.33b

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 301103 is expensive based on its Price-To-Sales Ratio (3.1x) compared to the CN Healthcare industry average (1.8x).

Price to Sales Ratio vs Fair Ratio

What is 301103's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301103 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.1x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 301103's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.8b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.77

-3.4%

-34.8%

Chison Medical Technologies

CN¥2.7b

Manufactures and sells diagnostic ultrasound systems in China and internationally.

688358

CN¥25.71

3.4%

-42.1%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.42

1.5%

35.8%